Sorafenib in locally advanced or metastatic breast cancer

Bibliography

• World Health Organization. Cancer Fact Sheet No. 297: WHO; 2011
   Google Scholar
• Barton S, Swanton C. Recent developments in treatment stratification for metastatic breast cancer. Drugs 2011;71:2099-113
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. NCCN; Washington: 2011
   Google Scholar
• Cardoso F, Fallowfield L, Costa A, Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi25-30
   PubMed Web of Science ®Google Scholar
• Jensen HM, Chen I, DeVault MR, Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 1982;218:293-5
   PubMed Web of Science ®Google Scholar
• Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23:1782-90
   PubMed Web of Science ®Google Scholar
• Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54:6504-11
   PubMed Web of Science ®Google Scholar
• Chan A. Antiangiogenic therapy for metastatic breast cancer: current status and future directions. Drugs 2009;69:167-81
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW, A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24
   PubMed Web of Science ®Google Scholar
• Bianchi G, Loibl S, Zamagni C, Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti Cancer Drugs 2009;20:616-24
   PubMed Web of Science ®Google Scholar
• Moreno-Aspitia A, Morton RF, Hillman DW, Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: north Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009;27:11-15
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Hurvitz S, Perez E, RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-93
   PubMed Web of Science ®Google Scholar
• Robert NJ, Dieras V, Glaspy J, RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60
   PubMed Web of Science ®Google Scholar
• Tanne JH. FDA cancels approval for bevacizumab in advanced breast cancer. BMJ 2011;343:d7684
   PubMedGoogle Scholar
• Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol 2011;29:1232-5
   PubMed Web of Science ®Google Scholar
• Pollack A. F.D.A. Revokes approval of avastin for use as breast cancer drug. Ny Times. November 19, 2011
   Google Scholar
• European Medicines Agency. EPAR summary for the public: Avastin. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000582/WC500029260.pdf [Accessed 16 November 2011]
   Google Scholar
• Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Ricotta R, Cerea G, Rationale and clinical results of multi-target treatments in oncology. Int J Biol Markers 2007;22:S77-87
   PubMed Web of Science ®Google Scholar
• Ding Q, Huo L, Yang JY, Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008;68:6109-17
   PubMed Web of Science ®Google Scholar
• Merz M, Komljenovic D, Zwick S, Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer 2011;47:277-86
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008;13:845-58
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-48
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37
   PubMed Web of Science ®Google Scholar
• Chang YS, Adnane J, Trail PA, Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8
   PubMed Web of Science ®Google Scholar
• Yu C, Bruzek LM, Meng XW, The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-9
   PubMed Web of Science ®Google Scholar
• Miller AA, Murry DJ, Owzar K, Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-5
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
   PubMed Web of Science ®Google Scholar
• Awada A, Hendlisz A, Gil T, Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80
   PubMed Web of Science ®Google Scholar
• Moore M, Hirte HW, Siu L, Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94
   PubMed Web of Science ®Google Scholar
• Strumberg D, Voliotis D, Moeller JG, Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002;40:580-1
   PubMedGoogle Scholar
• Awada A, Gil T, Whenham N, Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. J Clin Pharmacol 2011;51:1674-84
   PubMed Web of Science ®Google Scholar
• Bonelli MA, Fumarola C, Alfieri RR, Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat 2010;124:79-88
   PubMed Web of Science ®Google Scholar
• Richly H, Henning BF, Kupsch P, Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73
   PubMed Web of Science ®Google Scholar
• Awada A, Gil T, Whenham N, Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors [abstract 401]. Ann Oncol 2007;18(Suppl):iv39
   Google Scholar
• Bunone G, Briand PA, Miksicek RJ, Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83
   PubMed Web of Science ®Google Scholar
• Isaacs C, Herbolsheimer P, Liu MC, Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011;125:137-43
   PubMed Web of Science ®Google Scholar
• Baselga J, Segalla JGM, Roche H, Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Gradishar W, Kaklamani V, Prasad Sahoo T, A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC) [abstract 44]. Abstract and oral presentation at the 32nd Annual San Antonio Breast Cancer Symposium; Dec 9 – 13, 2009; San Antonio, TX
   Google Scholar
• Hudis C, Tauer KW, Hermann RC, Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV) [abstract 1009]. Abstract and oral presentation at the annual meeting of the American Society of Clinical Oncology; June 3 – 7, 2011; Chicago, IL
   Google Scholar
• Mariani G, Burdaeva O, Roman L, A double-blind, randomized phase IIb study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer: FM-B07-01 Trial [abstract 17LBA]. Abstract and oral presentation at the European Multidisciplinary Congress; Sept 23 – 27, 2011; Stockholm, Sweden
   Google Scholar
• Gradishar W, Dalenc F, Kaklamani V, Multivariate analysis of progression-free survival in 2 phase 2b, multinational, double-blind, randomized, placebo-controlled trials evaluating sorafenib plus standard chemotherapy in patients with HER2-negative locally advanced or metastatic breast cancer [abstract 1073]. Abstract and poster presentation at the annual meeting of the American Society of Clinical Oncology; June 4 – 8, 2010; Chicago, IL
   Google Scholar
• Bondarde S, Kaklamani V, Prasad Sahoo T, Sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer: overall survival results from a double-blind, randomized, placebo-controlled, phase 2b trial [abstract P2-16-03]. Abstract and poster presentation at the 33rd Annual San Antonio Breast Cancer Symposium; Dec 8 – 12, 2010; San Antonio, TX
   Google Scholar
• Sahoo TP, Kaklamani V, Lokanatha D, A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase 2b study evaluating sorafenib with paclitaxel in patients with advanced breast cancer [abstract 1114]. Abstract and poster presentation at the annual meeting of the American Society of Clinical Oncology; June 4 – 8, 2010; Chicago, IL
   Google Scholar
• Agarwal G, Pradeep PV, Aggarwal V, Spectrum of breast cancer in Asian women. World J Surg 2007;31:1031-40
   PubMed Web of Science ®Google Scholar
• Agarwal G, Ramakant P. Breast cancer care in India: the current scenario and the challenges for the future. Breast Care 2008;3:21-7
   PubMed Web of Science ®Google Scholar
• Chopra R. The Indian scene. J Clin Oncol 2001;19:106S-11S
   PubMed Web of Science ®Google Scholar
• Huggins RH, Kuzel TM, Anderson RT, Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL). J Clin Oncol 2008;26:abstract 16122
   Google Scholar
• Baselga J, Schwartzberg L, Petrenciuc O, Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC) [abstract TPS124]. Abstract and poster presentation at the annual meeting of the American Society of Clinical Oncology; June 3 – 7, 2011; Chicago, IL
   Google Scholar
• Mancuso MR, Davis R, Norberg SM, Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21
   PubMed Web of Science ®Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE, Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Garcia JA, Elson P, Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-6; discussion 86
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast 2011;20:S56-60
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007
   Google Scholar
• Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29:2439-42
   PubMed Web of Science ®Google Scholar
• Buyse M, Sargent DJ, Saad ED. Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol 2011;29:4719-20
   PubMed Web of Science ®Google Scholar
• Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21
   PubMed Web of Science ®Google Scholar
• Miles D, Harbeck N, Escudier B, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011;29:83-8
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Shaughnessy J, Loesch D, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23
   PubMed Web of Science ®Google Scholar
• Saad ED, Katz A, Hoff PM, Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7-12
   PubMed Web of Science ®Google Scholar
• D'Agostino RB Sr. Changing end points in breast-cancer drug approval–the Avastin story. N Engl J Med 2011;365:e2
   PubMedGoogle Scholar
• Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008;13:19-21
   PubMed Web of Science ®Google Scholar
• Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity [corrected]. Nat Rev Clin Oncol 2010;7:139-47
   PubMed Web of Science ®Google Scholar
• Alsina M, Ruiz-Echarri M, Capdevila J, Biomarkers for therapies directed at angiogenesis. Curr Colorectal Cancer Rep 2010;6:133-43
   Google Scholar
• Gianni L, Romieu G, Lichinitser M, First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) [abstract S4-8]. Cancer Res 2011;71:109s
   Google Scholar
• Bear HD, Tang G, Rastogi P, Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366(4):310-20
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Eidtmann H, Rezai M, Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366(4):299-309
   PubMed Web of Science ®Google Scholar
• Spigel DR, Hainsworth JD, Burris HA III, A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. Clin Adv Hematol Oncol 2011;9:280-6
   PubMedGoogle Scholar
• Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008;19:212-22
   PubMed Web of Science ®Google Scholar
• Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 2011;16:1508-19
   PubMed Web of Science ®Google Scholar